Casadei G, Grilli E, Piva A
Department of Veterinary Morphophysiology and Animal Production (DIMORFIPA), University of Bologna, 40064, Bologna, Italy.
J Anim Sci. 2009 Jun;87(6):2020-8. doi: 10.2527/jas.2008-1438. Epub 2009 Feb 27.
The aim of this study was to investigate in vitro the effects of pediocin A [a bacteriocin produced by lactic acid bacteria (LAB) Pediococcus pentosaceus FBB61] on microbial metabolism in the small and large intestine of pigs. Pediocin A was partially purified by ion exchange chromatography and added to an in vitro fermentation system. The intestinal inoculum was collected from pigs immediately after slaughter, diluted with a buffer, and dispensed into fermentation syringes and vessels of the 2 experimental groups: 1) Bac+ = cecal liquor + predigested diet + pediocin A (final concentration 160 activity units/mL); 2) Bac- = cecal liquor + predigested diet + partially purified supernatant of P. pentosaceus FBB61-2. Intestinal microbial growth was monitored using the cumulative gas production technique; the kinetics of fermentation, bacterial counts, VFA, ammonia, polyamines, and p-cresol production were analyzed. Pediocin A had almost no effects on small intestine fermentation parameters, whereas in the cecum pediocin A decreased gas production (-16%; P < 0.05), ammonia, and VFA production (-52 and -21%, respectively, after 24 h; P < 0.001) compared with the control group. Significant inhibition of clostridia and LAB occurred in cecal fermentations: the Bac+ group yielded a decreased number of clostridia and LAB in cecal fermentations (8.19 and 7.80 cfu/mL, respectively) compared with Bac- (9.32 and 8.95 cfu/mL, respectively; P < 0.001). The low clostridia counts in the pediocin-treated group may also explain the reduced concentration of the carcinogenic compound p-cresol (-88%; P < 0.01). Our results suggest that pediocin A could be an alternative to replace antibiotic growth promoters for the prophylaxis of enteric diseases and to improve production of farm animals.
本研究的目的是在体外研究片球菌素A[一种由乳酸菌(LAB)戊糖片球菌FBB61产生的细菌素]对猪小肠和大肠中微生物代谢的影响。通过离子交换色谱法对片球菌素A进行部分纯化,并将其添加到体外发酵系统中。屠宰后立即从猪身上采集肠道接种物,用缓冲液稀释,然后分配到2个实验组的发酵注射器和容器中:1)Bac+ = 盲肠液 + 预消化日粮 + 片球菌素A(终浓度160活性单位/mL);2)Bac- = 盲肠液 + 预消化日粮 + 戊糖片球菌FBB61-2的部分纯化上清液。使用累积产气量技术监测肠道微生物生长;分析发酵动力学、细菌计数、挥发性脂肪酸(VFA)、氨、多胺和对甲酚的产生情况。片球菌素A对小肠发酵参数几乎没有影响,而在盲肠中,与对照组相比,片球菌素A降低了产气量(-16%;P < 0.05)、氨和VFA的产生(24小时后分别降低-52%和-21%;P < 0.001)。在盲肠发酵中,梭菌和乳酸菌受到显著抑制:与Bac-组(分别为9.32和8.95 cfu/mL)相比,Bac+组在盲肠发酵中产生的梭菌和乳酸菌数量减少(分别为8.19和7.80 cfu/mL;P < 0.001)。片球菌素处理组中梭菌数量低也可能解释了致癌化合物对甲酚浓度的降低(-88%;P < 0.01)。我们的结果表明,片球菌素A可作为替代抗生素生长促进剂的一种选择,用于预防肠道疾病和提高农场动物的产量。